Royal Bank Of Canada Oncocyte Corp Transaction History

Royal Bank Of Canada

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.2 - $0.35 $551 - $964	2,756 Added 467.91%	3,345 $0
Q1 2023 May 15, 2023	SELL	$0.2 - $0.49 $10 - $26	-54 Reduced 8.4%	589 $0
Q4 2022 Feb 14, 2023	SELL	$0.25 - $15.6 $924 - $57,704	-3,699 Reduced 85.19%	643 $0
Q3 2022 Nov 14, 2022	BUY	$0.76 - $15.98 $2,848 - $59,893	3,748 Added 630.98%	4,342 $3,000
Q2 2022 Aug 15, 2022	SELL	$0.86 - $1.53 $3,472 - $6,178	-4,038 Reduced 87.18%	594 $1,000
Q1 2022 May 16, 2022	SELL	$1.15 - $2.25 $34,022 - $66,566	-29,585 Reduced 86.46%	4,632 $7,000
Q4 2021 Feb 14, 2022	BUY	$2.04 - $3.59 $52,311 - $92,058	25,643 Added 299.08%	34,217 $74,000
Q3 2021 Nov 15, 2021	BUY	$3.53 - $5.89 $8,535 - $14,242	2,418 Added 39.28%	8,574 $30,000
Q2 2021 Aug 16, 2021	BUY	$3.77 - $6.0 $23,208 - $36,936	6,156 New	6,156 $35,000

399K

Ticker OCX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,609,000
Market Cap $246M
Description
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay....

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.